



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Strength, Quantity, Refills, Directions, Diagnosis Code, Diagnosis.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a request for renewal of therapy with the requested drug (i.e., The requested drug has been previously approved on prior authorization)?

Yes No

Q2. Is the requested drug prescribed for the treatment of a diagnosis that is indicated in the United States Food and Drug Administration (FDA)-approved package labeling or a medically accepted indication?

Yes No

Q3. Is the patient age-appropriate according to the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?

Yes No

Q4. Is the requested drug prescribed by or in consultation with an appropriate specialist (e.g., gastroenterologist, dermatologist, rheumatologist, ophthalmologist, immunologist, genetic specialist, etc.)?

Yes No

Q5. If currently using a different Cytokine and CAM Antagonist, will discontinue the use of that Cytokine and CAM Antagonist prior to starting the requested medication or requires the use of 2 Cytokine antagonists according to peer-reviewed medical literature, or has 2 or more diseases for which a single agent is not sufficient.

Yes No

Q6. Does the patient have any contraindications to the requested drug?

Yes No



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q7. Is the prescribed dose and duration of therapy consistent with the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q8. Is the requested drug associated with an increased risk of infection according to the Food and Drug Administration (FDA)-approved package labeling?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Has the patient been evaluated for active or latent tuberculosis infection documented by results of a tuberculin skin test (purified protein derivative [PPD]) or blood test (interferon-gamma release assay)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Has the patient been evaluated for Hepatitis B infection documented by results of anti-HBs, HBsAg, and anti-HBc.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Is the requested drug associated with behavioral and/or mood changes as stated in the Food and Drug Administration (FDA)-approved package labeling (e.g., Otezla, Siliq)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. Has the patient been evaluated for a history of prior suicide attempt, bipolar disorder or major depressive disorder?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q13. Does the patient have a diagnosis of moderate-to-severe Crohn's disease?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Has the patient failed to achieve remission with or has a contraindication or intolerance to an induction course of corticosteroids?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Has the patient failed to maintain remission with an immunomodulator in accordance with current consensus guidelines OR does the patient have a contraindication or intolerance to immunomodulators in accordance with current consensus guidelines?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Does the patient have a diagnosis of Crohn's disease that is associated with one or more high-risk or poor prognostic features?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Has the patient achieved remission with the requested drug?</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q18. Will the requested drug be used as maintenance therapy to maintain remission?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q19. Does the patient have a diagnosis of ulcerative colitis (UC)?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q20. Does the patient have mild ulcerative colitis associated with multiple poor prognostic factors?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q21. Is the ulcerative colitis moderate-to-severe?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q22. Has the patient failed to achieve remission with or has a contraindication or intolerance to an induction course of corticosteroids?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q23. Has the patient failed to maintain remission with an immunomodulator in accordance with current consensus guidelines OR does the patient have a contraindication or intolerance to immunomodulators in accordance with current consensus guidelines?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q24. Has the patient achieved remission with the requested drug?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q25. Will the requested drug be used as maintenance therapy to maintain remission?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q26. Does the patient have a diagnosis of moderately-to-severely active rheumatoid arthritis?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q27. Does the patient have a history of therapeutic failure of a 3-month trial of a conventional non-biologic disease-modifying antirheumatic drug (DMARD) in accordance with current consensus guidelines?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q28. Does the patient have a contraindication or intolerance to conventional non-biologic disease-modifying antirheumatic drugs (DMARDs)?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q29. Does the patient have a diagnosis of juvenile idiopathic arthritis (JIA)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q30. Does the patient have a history of therapeutic failure, contraindication or intolerance to a 3-month trial of a conventional non-biologic disease-modifying antirheumatic drug (DMARD)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q31. Does the patient have systemic juvenile idiopathic arthritis (JIA) with active systemic features?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q32. Does the patient have a diagnosis of juvenile idiopathic arthritis (JIA) with involvement of high-risk joints, high disease activity, or at high risk of disabling joint damage ?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q33. Does the patient have active sacroilitis and/or enthesitis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q34. Does the patient have a history of therapeutic failure of a two-week trial of an oral non-steroidal anti-inflammatory drug (NSAID)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q35. Does the patient have a contraindication or intolerance to oral nonsteroidal anti-inflammatory drugs (NSAIDs)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q36. Does the patient have a diagnosis of ankylosing spondylitis or other axial spondyloarthritis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q37. Does the patient have a history of therapeutic failure of a 2-week trial of continuous treatment with two different oral nonsteroidal anti-inflammatory drugs [NSAIDs] (i.e., an oral NSAID taken daily for two weeks and a different oral NSAID taken daily for 2 weeks)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q38. Does the patient have a contraindication or intolerance to oral nonsteroidal anti-inflammatory drugs (NSAIDs)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q39. Does the patient have a diagnosis of active psoriatic arthritis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q40. Does the patient have axial disease and/or enthesitis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q41. Does the patient have peripheral disease?
Q42. Does the patient have history of therapeutic failure of an eight-week trial of a conventional non-biologic disease-modifying anti-inflammatory drug (DMARD), or a contraindication or intolerance to conventional non-biologic DMARDs?
Q43. Does the patient have severe disease as determined by the prescriber?
Q44. Does the patient have concomitant moderate-to-severe nail disease?
Q45. Does the patient have a diagnosis or moderate-to-severe chronic psoriasis?
Q46. Does the patient have psoriasis associated with at least one of the following: A) A body surface area (BSA) of 3 percent or more that is affected, B) A BSA of less than 3 percent that is affected with involvement of critical areas, C) Significant disability or impairment of physical or mental functioning?
Q47. Does the patient have history of therapeutic failure of topical corticosteroids or other topical pharmacologic therapy?
Q48. Does the patient have a contraindication or intolerance to topical corticosteroids and other topical pharmacologic therapy?
Q49. Does the patient have a diagnosis of moderate-to-severe hidradenitis suppurativa?
Q50. Does the patient have Hurley stage II or stage III disease?
Q51. Does the patient have a history of therapeutic failure, contraindication or intolerance to both of the following: A) A three-month trial of topical clindamycin, B) An adequate trial of systemic antibiotics OR Hurley stage III disease and is a candidate for or has a history of surgical intervention?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q52. Does the patient have a diagnosis of non-infectious uveitis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q53. Is the diagnosis of uveitis associated with juvenile idiopathic arthritis (JIA) or Behcet's syndrome?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q54. Does the patient have a history of therapeutic failure, contraindication or intolerance to one of the following: A) A systemic, topical, intraocular or periocular corticosteroid or B) A conventional systemic immunosuppressive?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q55. Does the patient have corticosteroid-dependent uveitis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q56. Will the requested drug be used with the intent of discontinuing or decreasing the dose of the systemic corticosteroid?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q57. Does the patient have a diagnosis of giant cell arteritis?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q58. Does the patient have history of therapeutic failure, contraindication or intolerance to systemic glucocorticoids?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q59. Is the patient at high-risk for glucocorticoid-related complications?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q60. Does the patient have glucocorticoid-dependent disease?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q61. Will the requested drug be used with the intent of discontinuing or decreasing the dose of the systemic glucocorticoid?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q62. Does the patient have a diagnosis of familial Mediterranean fever?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q63. Does the patient have a history of therapeutic failure of at least a three-month trial with colchicine at maximally tolerated doses or a contraindication or intolerance to colchicine?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q64. Does the patient have a diagnosis of Behcet's syndrome?
Q65. Has the diagnosis of Behcet's syndrome been confirmed by current consensus guidelines?
Q66. Does the patient have recurrent ulcers associated with Behcet's syndrome?
Q67. Does the patient have a history of therapeutic failure with, contraindication or intolerance to a topical corticosteroid (e.g., triamcinolone dental paste)?
Q68. Does the patient have a history of one of the following: A) Therapeutic failure of an adequate trial of colchicine at maximally tolerated doses or B) A contraindication or intolerance to colchicine?
Q69. Does the patient have a diagnosis of adult-onset Still's disease?
Q70. Does the patient have predominantly systemic disease?
Q71. Does the patient have a history of therapeutic failure, contraindication or intolerance to systemic glucocorticoids?
Q72. Does the patient have glucocorticoid-dependent Still's disease?
Q73. Will the requested drug be used with the intent of discontinuing or decreasing the dose of the systemic glucocorticoid?
Q74. Does the patient have predominantly joint disease?
Q75. Does the patient have a history of one of the following: A) Therapeutic failure of a conventional non-biologic DMARD or B) A contraindication or intolerance to conventional non-biologic DMARDs?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q76. Is the request for Arcalyst (rilonacept)?
Q77. Does the patient have a history of therapeutic failure, contraindication or intolerance of Kineret (anakinra) if approved or medically accepted for the beneficiary's diagnosis?
Q78. Does the patient have a current history of (within the past 90 days) of being prescribed Arcalyst (rilonacept)?
Q79. Is the request for Ilaris (canakinumab)?
Q80. Does the patient have a history of therapeutic failure, contraindication or intolerance to Kineret (anakinra) if approved or medically accepted for the patient's diagnosis?
Q81. Does the patient have a current history of (within the past 90 days) of being prescribed Ilaris (canakinumab)?
Q82. Is this request for an infliximab product other than Avsola (infliximab-axxg)?
Q83. Does the patient have history of therapeutic failure, contraindication or intolerance of Avsola (infliximab-axxg) if approved or medically accepted for the diagnosis?
Q84. Does the patient have a current history of (within the past 90 days) of being prescribed infliximab?
Q85. Is the request for a non-preferred cytokine or cell adhesion molecule (CAM) antagonist?
Q86. Does the patient have a history of therapeutic failure, contraindication or intolerance to the preferred cytokine or cell adhesion molecule (CAM) antagonists approved or medically accepted for the diagnosis?
Q87. Has the patient been prescribed the same non-preferred cytokine or cell adhesion molecule (CAM) antagonist within the past 90 days?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Cytokine and CAM Antagonists

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name: Prescriber Name:

Q88. Has the patient experienced improvement in disease activity and/or level of functioning since initiating therapy with the requested cytokine and cell adhesion molecule (CAM) antagonist?
Q89. Is the requested drug prescribed by or in consultation with an appropriate specialist (e.g., gastroenterologist, dermatologist, rheumatologist, ophthalmologist, immunologist, genetic specialist, etc.)?
Q90. Is the prescribed dose and duration of therapy consistent with the Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia or peer-reviewed medical literature?
Q91. Have all potential drug interactions been addressed by the prescriber (such as discontinuation of the interacting drug, dose reduction of the interacting drug or counseling of the beneficiary about the risks associated with the use of both medications when they interact)?
Q92. Is the patient currently taking any other cytokine or cell adhesion molecule (CAM) antagonist?
Q93. Is the requested drug associated with behavioral and/or mood changes as stated in the Food and Drug Administration (FDA)-approved package labeling?
Q94. Has the patient been evaluated for behavioral and mood changes as recommended in the Food and Drug Administration (FDA)-approved package labeling?
Q95. Requested Duration:
Q96. Additional Information:

Prescriber Signature

Date

Updated for 2022